Definition and delineation of the clinical target volume for rectal cancer.
about
The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West.Dosimetric coverage of the external anal sphincter by 3-dimensional conformal fields in rectal cancer patients receiving neoadjuvant chemoradiation: implications for the concept of sphincter-preserving radiation therapy.Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting.Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial.Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer.Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical TrialPatients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rateComparison of conventional and three-dimensional conformal CT planning techniques for preoperative chemoradiotherapy for locally advanced rectal cancer.Optimizing adjuvant treatment decisions for stage t2 rectal cancer based on mesorectal node size: a decision analysisPhase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.Intensity-modulated radiation therapy for pelvic oligo-recurrence from rectal cancer: long-term results from a single institution.Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case.Patterns of local recurrence in rectal cancer: a single-center experience.IGRT in rectal cancer.Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trialInterim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.Neo-adjuvant radiotherapy in rectal cancer.Automatic segmentation software in locally advanced rectal cancer: READY (REsearch program in Auto Delineation sYstem)-RECTAL 02: prospective study.Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.A dosimetric evaluation of knowledge-based VMAT planning with simultaneous integrated boosting for rectal cancer patients.Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancerPreoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results.Inflatable multichannel rectal applicator for adaptive image-guided endoluminal high-dose-rate rectal brachytherapy: design, dosimetric characteristics, and first clinical experiences.Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors.Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancerComparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer.Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with locally advanced rectal cancerTarget volume delineation for preoperative radiotherapy of rectal cancer: inter-observer variability and potential impact of FDG-PET/CT imaging.Laparoscopic salvage surgery for locally recurrent rectal cancer.Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy.Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer.Differing Serum Cea in Primary and Recurrent Rectal Cancer - A Reflection of Histology?Photon Optimizer (PO) prevails over Progressive Resolution Optimizer (PRO) for VMAT planning with or without knowledge-based solution.Feasibility of preference-driven radiotherapy dose treatment planning to support shared decision making in anal cancer.Clinical validation of atlas-based auto-segmentation of pelvic volumes and normal tissue in rectal tumors using auto-segmentation computed system.FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases.FDG PET/CT for rectal carcinoma radiotherapy treatment planning: comparison of functional volume delineation algorithms and clinical challenges.
P2860
Q33312830-CED89517-7094-425C-A71D-94E627630768Q33893811-33891CBE-9048-4C2F-A992-E485CB8090FAQ34088596-451906EB-F96B-422B-82F2-35486917616AQ34719568-57C664E8-3131-4229-9E0B-AD7114E7554DQ35131972-FD01F7CE-058F-4E11-9689-08A8AD10424EQ35542484-D84D7F18-DCC3-45FD-A592-0F1D9C323951Q35920508-DE7B1E94-1FF2-49B1-857E-C5A13F92DF66Q36043758-B263CBDD-B9E3-4676-85AA-CAC6DDF65318Q36303226-A9C8F539-7EAC-494D-B341-1CEF3A64EC80Q36325238-218A84DB-D3B2-40C0-8503-23605EA39A8AQ36476409-794CA8CA-8F7A-4C7C-84D7-2808322560ABQ36555815-F1CC3AF3-E428-47A3-A99E-CD35666D7864Q36841401-16232228-14B9-49DC-A513-0E2DA24604A7Q37038061-1F682545-8A1A-4638-8BD4-0D930F663D63Q37171180-BACF969F-3E69-4C67-B790-EDAEE085F285Q37228663-D3B6E1F0-792C-4B39-B439-67CCD081A4F4Q37258339-DCA19714-5DAA-485E-BFEC-EA299A3DE87DQ37272825-49D99C76-C569-4741-A074-3BC80210EEAAQ37295422-D10A512A-47CD-4267-A1ED-450EF24246A1Q37408813-40A59CB8-E3AF-4C26-B560-91505F5D4071Q37520623-B22950A6-31EB-4A8B-8533-B5D5E260E452Q37699754-231B2AD4-E268-46F6-BE9B-68CA7DEFC1DBQ38905841-BA8DA2A9-12D9-4C8F-9F8F-4E9C0F92309FQ39103454-EA5481BF-A0AD-4C76-B506-43CEE9E30E30Q39800548-9EC3F3EE-58B7-4423-9605-7EC54204A0E0Q41689153-17E21FCC-832E-436D-A6C1-1B149FE54371Q42121875-7BF88B87-04F6-463E-BB52-548353333D39Q42380318-05E170EA-691C-4EAC-8B6F-9F7B1ABE4C43Q42794358-4C2A1C70-C083-4DF1-9784-41645B681F1FQ42794535-8BF7F7C4-DC52-46CB-AAAF-42056827ED7FQ42971952-10AE887B-22A6-4D81-AD5A-4E994476B343Q44380291-C80E1F6A-F5AF-41E5-B6F9-9304EFA7DF14Q45983757-5AFB32A0-61BE-43E4-8017-B404108B2EBEQ46049376-1283728E-FFD5-4816-AA1C-AF73EA4820C3Q47117987-78B00EE0-BE0D-4469-A106-294717480B44Q47927379-9F64F8BA-CC22-48AB-9926-585BEBAEC4F3Q48226496-108BB2B2-77B9-437C-99DD-A6F5670162E6Q48314129-A095FCF0-0B4C-4081-9B56-F4E1232E5C15Q50673731-5D5C61CB-260B-48A1-8881-E6D3D2758ADBQ51040212-B0864027-686D-46F9-A2AC-547548889885
P2860
Definition and delineation of the clinical target volume for rectal cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Definition and delineation of the clinical target volume for rectal cancer.
@ast
Definition and delineation of the clinical target volume for rectal cancer.
@en
type
label
Definition and delineation of the clinical target volume for rectal cancer.
@ast
Definition and delineation of the clinical target volume for rectal cancer.
@en
prefLabel
Definition and delineation of the clinical target volume for rectal cancer.
@ast
Definition and delineation of the clinical target volume for rectal cancer.
@en
P2093
P1476
Definition and delineation of the clinical target volume for rectal cancer.
@en
P2093
Freddy Penninckx
Karin Haustermans
Sarah Roels
Tom Boterberg
Vincent Vandecaveye
Wilfried De Neve
Wim Duthoy
P304
P356
10.1016/J.IJROBP.2006.02.050
P407
P577
2006-06-05T00:00:00Z